… Creatinine clearance (CrCl) was calculated using a lean body weight estimate formula in
the Cockcroft–Gault equation based on its performance in morbid obesity [20]. …

… currently used piperacillin/tazobactam dosing regimens in obese and nonobese patients. For
… I Standard body weight, II lower BMI threshold for morbid obesity, III healthy renal function […

… (35) Most (80%) patients received extendedinfusion piperacillin/tazobactam (3.375gq 8 hours
… non-obese, obese, and morbidly obese patients and that weight alone should not prompt …

… Piperacillin-tazobactam dosing overseen by clinical pharmacy practitioners were adjusted
as necessary based on renal function and indication per discussion with the primary admitting …

… dosing of piperacillin-tazobactam is suboptimal for patients in … of piperacillin-tazobactam
popPK models is currently available. As the amount of information on piperacillin-tazobactam …

… piperacillin–tazobactam therapy ≤ 72 h before inclusion, and were managed with a central
venous and/or arterial catheter. Patients … Dose and duration of piperacillin–tazobactam were …

… In conclusion, the findings recommend dosing of piperacillin-tazobactam with the aim of
achieving a pharmacodynamic target %fT >MIC of at least 60% in these patients. …

… Similar conclusion was recently reported with meropenem and piperacillin-tazobactam, with
… Among the two reports of morbid obesity included in this review, both patients had altered …

… Moreover, we investigated appropriate dosage regimens of piperacillin/tazobactam via
Monte Carlo simulations to predict the standard and aggressive PK/PD indices of 50%fT >MIC , …

… based on TBW and TDM at trough concentrations, which may not be optimal for obese and
severely obese patients because an increase in the V d of vancomycin with weight has been …